

LIFE – STRATEGIC INVESTMENT IN REMOVEAID AS

Bergen, Norway, 26th April 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), intend to invest NOK 2 million and become the majority shareholder in RemovAid AS, a medical technology company based in Oslo, Norway.

RemovAid is an ISO 13485 certified company who specializes in the development, manufacture and distribution of medical devices which remove subdermal implants. RemovAid has developed and patented an CE certified a class IIa medical device for gentle and efficient removal single-rod contraceptive implants.

About us

Lifecare AS is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's main focus is to bring the next generation of Continuous Glucose Monitoring ("CGM") systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR") on the sensor body for read-out of pressure variations. Lifecare's sensor technology is referred to as "Sencell" and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

Asle Wingsternes, Head of Communications & Public Affairs, asle.wingsternes@lifecare.no,
+47 41 61 42 52

This information has been submitted pursuant to the Securities Trading Act § 5-12 and MAR Article 19 no. 3. The information was submitted for publication at 2024-04-26 13:29 CEST.